Literature DB >> 15888138

Current severe psoriasis and the rule of tens.

A Y Finlay1.   

Abstract

This review addresses the problems of defining severity of psoriasis. Concepts of severity depend on the timescale perspective from which judgement is made. Measurement needs to include assessment of signs, impact on the patient's life and the history of the disease. The concept of severity in relationship to quality of life measurement scores has been defined, so it is now possible to postulate a standard, easily remembered concept to help define 'severe psoriasis' in the clinic. The proposed Rule of Tens for current severe psoriasis from the clinician's viewpoint is: 'Current Severe Psoriasis = Body Surface Area involved > 10% or Psoriasis Area and Severity Index score > 10 or Dermatology Life Quality Index score > 10'.

Entities:  

Mesh:

Year:  2005        PMID: 15888138     DOI: 10.1111/j.1365-2133.2005.06502.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  53 in total

Review 1.  Psoriasis--new insights into pathogenesis and treatment.

Authors:  Ulrich Mrowietz; Kristian Reich
Journal:  Dtsch Arztebl Int       Date:  2009-01-05       Impact factor: 5.594

2.  Emotion Regulation in Patients with Psoriasis: Correlates of Disability, Clinical Dimensions, and Psychopathology Symptoms.

Authors:  Vera Almeida; Sofia Taveira; Maribel Teixeira; Isabel Almeida; José Rocha; Ana Teixeira
Journal:  Int J Behav Med       Date:  2017-08

Review 3.  Management of psoriasis patients with hepatitis B or hepatitis C virus infection.

Authors:  Claudio Bonifati; Viviana Lora; Dario Graceffa; Lorenzo Nosotti
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

4.  Which Psoriasis Patients Develop Psoriatic Arthritis?

Authors:  Kristine Busse; Wilson Liao
Journal:  Psoriasis Forum       Date:  2010

5.  HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.

Authors:  Marina Talamonti; Marco Galluzzo; Arianna Zangrilli; Marina Papoutsaki; Colin Gerard Egan; Mauro Bavetta; Sara Tambone; Maria Concetta Fargnoli; Luca Bianchi
Journal:  Mol Diagn Ther       Date:  2017-06       Impact factor: 4.074

6.  Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Authors:  Kim A Papp; James Signorovitch; Karthik Ramakrishnan; Andrew P Yu; Shiraz R Gupta; Yanjun Bao; Parvez M Mulani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 7.  Psoriasis: advances in pathophysiology and management.

Authors:  A MacDonald; A D Burden
Journal:  Postgrad Med J       Date:  2007-11       Impact factor: 2.401

8.  Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis.

Authors:  E D Dommasch; D B Shin; A B Troxel; D J Margolis; J M Gelfand
Journal:  Br J Dermatol       Date:  2009-11-10       Impact factor: 9.302

Review 9.  [Therapeutic strategies for psoriasis and psoriatic arthritis].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2009-02       Impact factor: 0.751

10.  Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.